Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 817-823

  Lanic, Hélène ^a,b   Kraut Tauzia, Jerôme ^a   Modzelewski, Romain ^a   Clatot, Florian ^a,b   Mareschal, Sylvain ^a,b   Picquenot, Jean Michel ^b,c   Stamatoullas, Aspasia ^a,b   Leprêtre, Stéphane ^a,b   Tilly, Hervé ^a,b   Jardin, Fabrice ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITY OF ROUEN   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

Albuminemia; Diffuse large B cell lymphoma; Elderly; Prognosis; R CHOP; Sarcopenia

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; VINCRISTINE;

AGED; ANTHROPOMETRY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; FEMALE; GERIATRIC PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SARCOPENIA; VERY ELDERLY; AGE; BODY MASS; BODY SURFACE; COMPLICATION; COMPUTED TOMOGRAPHY SCANNER; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; ORGAN SIZE; PATHOLOGY; RETROSPECTIVE STUDY; SKELETAL MUSCLE; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MUSCLE, SKELETAL; ORGAN SIZE; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TREATMENT OUTCOME; VINCRISTINE;

EID: 84904295562     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.816421     Document Type: Article

References (27)

1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276. (Pubitemid 43053551)
2. d'Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 1992;3:379-386.
3. van de Schans SA, Wymenga AN, van Spronsen DJ, et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280-1286.
4. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immuno- chemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.
5. Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011; 96: 1888-1890.
6. Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119: 1882-1887.
7. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011; 137: 1079-1084.
8. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin 's lymphoma. J Clin Oncol 2010; 28: 4191-4198.
9. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012; 30: 1829-1834.
10. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763. (Pubitemid 28183275)
11. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.Clin Cancer Res 2007; 13: 3264-3268. (Pubitemid 46944911)
12. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-6979.
13. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635.
14. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-2926.
15. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594-1598.
16. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
17. Mourtzakis M, Graham TE, Gonzalez-Alonso J, et al. Glutamate availability is important in intramuscular amino acid metabolism and TCA cycle intermediates but does not affect peak oxidative metabolism. JAppl Physiol 2008;105:547-554.
18. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
19. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
20. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3:269-275.
21. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross- sectional image. J Appl Physiol 2004;97:2333-2338. (Pubitemid 39552474)
22. Prado RP, Pinfildi CE, Liebano RE, et al. Effect of application site of low-level laser therapy in random cutaneous flap viability in rats. Photomed Laser Surg 2009; 27: 411-416.
23. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-1137S.
24. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997-1006.
25. Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774-779. (Pubitemid 351461051)
26. Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3217-3222.
27. Muller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276-3284.